The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.
The Cancer Journal documented 25 cases where inappropriate tests were ordered, variants were interpreted incorrectly, and wrong results were reported to patients.
In a pilot study, EMD Serono will have the genomes of lung cancer patients sequenced for research but participants will also gain access to their genomic data.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
